EUVIMEDEUVIMED entdecken
Multizentrische Studie

Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis

Inês Leonor Leitão, Carla Mimoso Santos, Paulo André, Sara Lino, Marcos Lemos, Filipe Froes

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2023

DOI: 10.1016/j.eimce.2021.12.017 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2023. Verfasst von Inês Leonor Leitão und 5 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Department, Santa Maria Hospital - Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Infectious Diseases Clinic, Li…. Hauptthemen laut MEDLINE: Pseudomonas Infections, Cephalosporins, Tazobactam, Anti-Bacterial Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Pseudomonas aeruginosa displays resistance to several available antibiotics. Infections caused by this pathogen are associated with a high mortality, morbidity, and considerable healthcare resource utilization and costs. This study was aimed at describing the use of ceftolozane/tazobactam (C/T) for the treatment of patients with P. aeruginosa infections. METHODS: Case series analysis of hospitalized patients treated with C/T for P. aeruginosa infections in five public Portuguese hospitals. Patients presenting with infections caused by this pathogen and receiving C/T for at least 72h during hospitalization were eligible. RESULTS: Sixty-four hospitalized patients with P. aeruginosa infections treated with C/T were evaluated between December 2016 and July 2019. Most patients were aged between 60 and 79 years (53.9%). Patients presented a total of 68 P. aeruginosa infections, with respiratory infections being the most common (28.1%, 18 out of 64). Most P. aeruginosa strains (85.9%, 55 out of 64) were extensively drug-resistant (XDR). C/T was mostly used as targeted therapy (98.4%, 63 out of 64 patients) and as monotherapy (72.7%, 47 out of 64 patients). Combination therapy was used in 47.4% (9 out of 19) of patients with bacteriemia. Most patients had successful microbiological (79.2%, 42 out of 53) and clinical (78.7%, 48 out of 61) outcomes. All-cause in-hospital mortality rate was 34.4%. CONCLUSION: The present case series contributes to the body of evidence suggesting that C/T is an effective and safe option for treating P. aeruginosa infections, namely those caused by XDR strains, both when used as mono- or combination therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pseudomonas InfectionsCephalosporinsTazobactamAnti-Bacterial AgentsPseudomonas aeruginosaHumansAgedMiddle AgedMaleFemaleAged, 80 and overAdultRetrospective StudiesDrug Resistance, Multiple, BacterialPortugal

Stichwörter der Autor:innen

Ceftolozane–tazobactamCeftolozano/tazobactamHospital infectionsInfección hospitalariaMultidrug resistanceMultirresistenciaPseudomonas aeruginosa

Substanzen

ceftolozane, tazobactam drug combinationCephalosporinsTazobactamAnti-Bacterial Agents

Autor:innen und Institutionen

  • Infectious Diseases Department, Santa Maria Hospital - Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Infectious Diseases Clinic, Lisbon University Faculty of Medicine, Lisbon, Portugal.
  • Infectious Diseases Department, Santa Maria Hospital - Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal; Infectious Diseases Clinic, Lisbon University Faculty of Medicine, Lisbon, Portugal. Electronic addr…
  • Intensive Care Unit, Centro Hospitalar Barreiro-Montijo, Barreiro, Portugal.
  • Infectious Diseases Clinic, Lisbon University Faculty of Medicine, Lisbon, Portugal; Infectious Diseases Department, Curry Cabral Hospital - Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
  • Clinical Hematology Department, Santo António dos Capuchos Hospital - Centro Hospitalar Universitário Lisboa Central, Lisbon, Portugal.
  • Chest Department, Pulido Valente Hospital - Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.

Zitieren

APA

Leitão, I. L., Mimoso Santos, C., André, P., Lino, S., Lemos, M., & Froes, F. (2023). Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis. Enfermedades infecciosas y microbiologia clinica (English ed.). https://doi.org/10.1016/j.eimce.2021.12.017

Vancouver

Leitão IL, Mimoso Santos C, André P, Lino S, Lemos M, Froes F. Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis. Enfermedades infecciosas y microbiologia clinica (English ed.). 2023. doi:10.1016/j.eimce.2021.12.017

BibTeX
@article{Leito2023,
  author = {Leitão, Inês Leonor and Mimoso Santos, Carla and André, Paulo and Lino, Sara and Lemos, Marcos and Froes, Filipe},
  title = {Ceftolozane/tazobactam for the treatment of Pseudomonas aeruginosa infections: A multicenter case series analysis},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2023},
  doi = {10.1016/j.eimce.2021.12.017}
}
Kostenlos starten →